10-K: SeaStar Medical Reports 2024 Results, Highlights FDA-Approved Pediatric Device and Ongoing Adult AKI Trial

SeaStar Medical's 10-K filing details its 2024 financial results, commercial progress with its FDA-approved pediatric device, and ongoing clinical trials for its adult AKI therapy.

Summary

• SeaStar Medical, a commercial-stage healthcare company, focuses on treatments for critically ill patients facing organ failure.
• The company's Selective Cytopheretic Device (SCD) aims to neutralize over-active immune cells and stop the cytokine storm.
• The FDA approved the pediatric SCD therapy on February 21, 2024, under a Humanitarian Device Exemption (HDE).
• The first commercial pediatric SCD (QUELIMMUNE) was shipped in July 2024.
• A pivotal clinical trial is underway to assess the SCD therapy's safety and efficacy in critically ill adult patients with AKI.
• The company has enrolled 94 patients in the pivotal trial as of March 25, 2025, and anticipates reporting topline results and submitting a PMA application in 2026.
• The FDA has granted Breakthrough Device Designation (BDD) for four therapeutic indications.
• The company's patent portfolio includes 34 patents and 7 pending patent applications in the U.S. and certain foreign jurisdictions.
• The company had an accumulated deficit of $139.6 million as of December 31, 204, and a net loss of $24.8 million for the year.
• The company's management believes that its cash and cash equivalents are not sufficient to meet its operations, working capital and capital expenditure requirements for a period of at least twelve months from the date of its audited consolidated financial statements for the fiscal year ended December 31, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as FDA approval and initial commercial sales, the company faces significant financial challenges, including substantial losses, negative working capital, and the need for additional funding. The going concern warning also weighs heavily on the sentiment.

Positives

• FDA approval and initial commercial sales of QUELIMMUNE for pediatric AKI.
• Ongoing pivotal clinical trial for SCD therapy in adult AKI patients.
• Breakthrough Device Designation (BDD) granted by the FDA for multiple therapeutic indications.
• Strong patent portfolio with 34 patents and 7 pending applications.
• Demonstrated reduction in 60-day mortality of 50% in SCD-treated patients in COVID-19 related AKI or ARDS study.
• Demonstrated survival rate of ~77% at Day 60 in pediatric patients weighing at least 10 kg in combined pooled analysis of PED-01 and PED-02 studies.

Negatives

• Significant accumulated deficit of $139.6 million as of December 31, 2024.
• Net losses of $24.8 million for the year ended December 31, 2024.
• Limited operating history and dependence on a single product (QUELIMMUNE) for revenue.
• Reliance on third-party suppliers for critical components.
• Negative working capital of $3.0 million as of December 31, 2024.
• The company's management believes that its cash and cash equivalents are not sufficient to meet its operations, working capital and capital expenditure requirements for a period of at least twelve months from the date of its audited consolidated financial statements for the fiscal year ended December 31, 2024.

Risks

• The company may not be able to obtain additional FDA approvals to market its products.
• Delays in clinical trials could jeopardize the ability to obtain regulatory approval.
• The company faces intense competition in the medical device industry.
• A lack of third-party coverage and reimbursement for the devices could delay or limit their adoption.
• The company depends on key personnel, and the inability to attract and retain qualified personnel could impede the ability to achieve business objectives.
• The company relies upon exclusively licensed patent rights from third parties which are subject to termination or expiration.
• The company may redeem unexpired warrants prior to their exercise at a time that is disadvantageous to warrant holders.
• The trading price of the company's Common Stock has been volatile and is likely to be volatile in the future.
• The company may suffer from lack of availability of additional funds.
• The company may become a defendant in one or more stockholder derivative, class-action, and other litigation, and any such lawsuits may adversely affect our business, financial condition, results of operations and cash flows.

Future Outlook

The company anticipates reporting topline clinical trial results and submitting a PMA application in 2026. The company expects to continue to incur significant and increasing losses and negative cash flows for the foreseeable future.

Industry Context

The industry for treating inflammation is extremely competitive, and companies developing new treatment procedures face significant capital and regulatory challenges. The AKI market needs new and effective solutions, and hospitals continue to search for and evaluate new products.

Comparison to Industry Standards

• The two largest operators in the CRRT market by revenue are Fresenius Medical Care Holdings, Inc. and Baxter International, which represent over 80% of the market today in the U.S.
• A 2017 study stated hospital costs associated with AKI in the U.S. are between $5.4 billion and $20 billion per year.
• According to Hobson in his article titled Cost and Mortality Associated with Postoperative Acute Kidney Injury, a 2015 study of 50,314 patients (over 11 years) found that upon greater scrutiny, AKI was found in 39% of post-surgical patients, and 19% of patients had stage 2 or 3 AKI with an average incremental cost of $29,800 per patient.
• The AKI patient population is growing on average 6.9% per year according to the Healthcare Cost and Utilization Project commissioned by the Agency for Healthcare Research and Quality, a U.S. federal agency.
• According to Massicotte and Azarniouch in their 2015 work titled Acute Kidney Injury in the Intensive Care Unit: Risk Factors and Outcomes of Physician Recognition Compared with KDIGO Classification, around 80% of moderate or severe cases of AKI are not diagnosed and documented, suggesting the U.S. AKI patient population is higher than the estimated 6 million patients annually.

Corporate Governance

Legal Proceedings

• Forrest A K Wells, a purported stockholder of the Company, filed a putative class action complaint in the United States District Court for the State of Colorado, captioned Wells v. SeaStar Medical Holding Corporation et al, Case No. 1:24-cv-0187 (D. Colorado) (the Class Action).
• Jose Lazo, a purported stockholder of the Company, filed a putative stockholder derivative action complaint captioned Lazo v. Schlorff et. al., C.A. No. 1:24-cv-3444 in the United States District Court for the District of Colorado (the Derivative Action).

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, volatility in stock price, and uncertainty regarding the company's ability to continue as a going concern.
• Employees: Job security may be affected by the company's financial challenges and potential need to reduce or suspend operations.
• Customers: Availability of products and services may be impacted by the company's financial challenges and reliance on third-party suppliers.
• Suppliers: Potential risk of delayed or reduced payments due to the company's financial challenges.
• Creditors: Increased risk of default on debt obligations due to the company's financial challenges.

Next Steps

• Continue pivotal clinical trial for SCD therapy in adult AKI patients.
• Report topline clinical trial results and submit a PMA application in 2026.
• Pursue additional clinical development of the SCD therapy in adults based on unmet clinical needs and market opportunity.
• Scale production with manufacturing partners to meet expected demand for solutions.
• Continue to develop a comprehensive reimbursement strategy including CMS, private payors and other key stakeholders to ensure a clear and sustainable reimbursement path for all SCD product opportunities.

Key Dates

Keywords

SCD, QUELIMMUNE, AKI, CRRT, FDA, Breakthrough Device Designation, Clinical Trial, Hyperinflammation, Kidney Injury, Medical Device